Parsippany, NJ and Melbourne, Australia-based d3 Medicine provides strategic planning services for complex drug development programs.
Per the acquisition, the d3 Medicine staff will be integrated into Certara’s Strategic Consulting (CSC) division, expanding Certara’s modeling and simulation and regulatory science expertise.
“Both companies focus on developing a deep understanding of clinical pharmacology and its impact on drug development,” d3 Medicine CEO Craig Rayner, PharmD, MBA, told Outsourcing-Pharma.com.
“d3 Medicine’s staff, with its experience working in clinical pharmacology and operational drug development in the pharma industry, will be an excellent fit for the modeling and simulation and regulatory science powerhouse that Certara has built over the past few years,” said Rayner.
Specifically, the addition of the d3 Medicine staff will provide Certara with capabilities in oncology, orphan diseases, infectious diseases and inflammation, as well as a new location in Australia.
Value focused development
“Success in the biopharm industry is no longer just based on achieving regulatory approval, but on demonstrating commercial differentiation for new drugs and reimbursement by payers,” explained Rayner.
In order to achieve this, Rayner said organizations need to implement a strategic and programmatic approach to drug development – one that addresses both “the probability of success and economic return.”
Certara calls this “value focused development.”
“As a team of drug development and regulatory science specialists, we are able to guide the client’s program by testing and evolving the strategy, and helping implement an optimized development program,” he explained, adding that the company is able to further differentiate itself via its quantitative toolkit of modeling and simulation – which the company claims has the largest portfolio and client base.
“Demand for all of these capabilities is growing exponentially,” said Rayner.